Obagi Medical price target lowered to $15 from $19 at Canaccord Canaccord lowered Obagi Medical sales growth estimates for 2013 due to a slower than expected transition towards an e-commerce platform. Shares remain Buy rated.
News For OMPI From The Last 14 Days
Check below for free stories on OMPI the last two weeks.
